Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11507644 | 0.86 | ADRB2 (0.49) | ADRB2NPC1RAB9A | |
| SCHEMBL23900516 | 0.85 | JAK2 (0.50) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2141200 | 0.85 | CTSS (0.48) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2141206 | 0.85 | CTSS (0.48) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL31407446 | 0.85 | ACE (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL31689508 | 0.85 | CTSS (0.54) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL15423693 | 0.85 | ATM (0.53) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL23273193 | 0.85 | ACE (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL23273192 | 0.85 | ACE (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL21799327 | 0.84 | CTSL (0.64) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| CN-1217936-C | Heterocyclic compounds having sulfonic acid | EISAI CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| CN-1414952-A | Heterocyclic compounds having sulfonic acid | EISAI CO LTD (JP) | 2003-04-30 | — | — | CN | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | CTSS 2880/4885CTSK 3690/4885CTSB 1112/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CTSS 2880/4885CTSK 3690/4885CTSB 1112/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | CTSS 2172/4885CTSK 3082/4885CTSB 970/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | CTSS 1613/4885CTSK 2836/4885CTSB 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.